FDA Approves Acorda's Ampyra

Ampyra, formerly known as fampridine SR, is a tablet containing a sustained-release formula of 4-aminopyridine, which blocks tiny pores, or potassium channels, on the surface of nerve fibers.

This blocking ability may improve the conduction of nerve signals in nerve fibers whose insulating myelin coating has been damaged by MS. The first studies of this potassium-blocking approach in people with MS were supported by the National MS Society.

Ampyra (dalfampridine) is a potassium channel blocker that enhances conduction in damaged nerves. The exact mechanism by which dalfampridine exerts its therapeutic effect has not been fully elucidated.
Ampyra is specifically inidicated as a treatment to improve walking in patients with multiple sclerosis.
Ampyra is supplied as an extended release tablet for oral administration. The maximum recommended dose of Ampyra is one 10 mg tablet twice daily, taken with or without food, and should not be exceeded. Doses should be taken approximately 12 hours apart. Patients should not take double or extra doses if a dose is missed.

Ampyra is a medication prescribed for the treatment of multiple sclerosis (MS). Specifically, this medicine is used to help improve walking in people with MS. It comes in the form of extended-release tablets and is typically taken twice daily. Possible side effects include headaches, dizziness, and insomnia.

Ampyra (dalfampridine) is a potassium channel blocker.

Ampyra is used to improve walking in patients with multiple sclerosis (MS). Dalfampridine produced an increase in walking speed in clinical trials. Exactly how it works is not known. It is thought to increase nerve function.